title: Decreased ADAMTS-13 level is related to inflammation factors and risk stratification of acute lymphoblastic leukemia patients.
abstract: As a kind of metalloprotease of the ADAMTS family, ADAMTS-13 is crucial for maintaining the normal size of von Willebrand factor. Reduced ADAMTS-13 had been reported in patients with both localized and disseminated malignancies. However, the expression and potential role of ADAMTS-13 in hematological malignancies remain unclear. In this research, we measured and compared ADAMTS-13 levels in plasma of 35 acute lymphoblastic leukemia (ALL) patients and 30 healthy controls and found that ALL patients possessed lower level of ADAMTS-13 than controls. Correlations between ADAMTS-13 and inflammation factors were calculated and ADAMTS-13 was negatively correlated with C-reactive protein and interleukin-1β. ALL patients with infections had lower level of ADAMTS-13 than patients without infections. In addition, high-risk ALL patients possessed lower ADAMTS-13 than patients at low risk. To conclude, ADAMTS-13 level is decreased in the plasma of ALL patients and the level of ADAMTS-13 is related to plasma inflammation factors and risk stratification of ALL patients, which could contribute to better understanding of the clinical significance of ADAMTS-13.
authors.affiliation: Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Liu
authors.forename: Lei
authors.initials: L
authors.lastname: Zhao
authors.forename: Jingzhong
authors.initials: J
authors.lastname: Zhao
authors.forename: Qinzhu
authors.initials: Q
authors.lastname: Xu
authors.forename: Ying
authors.initials: Y
authors.lastname: Song
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
mesh_terms: D000071120:ADAMTS13 Protein / Q000097:blood* / Q000378:metabolism; D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007239:Infections / Q000097:blood / Q000150:complications; D018836:Inflammation Mediators / Q000097:blood* / Q000378:metabolism; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000150:complications; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014841:von Willebrand Factor / Q000096:biosynthesis
chemical_list: D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D014841:von Willebrand Factor; D000071120:ADAMTS13 Protein